Bonum Therapeutics: The company raised $93 million through a combination of debt and Series A venture funding from Roche Venture Fund, 3×5 Partners and Codon Capital on November 15, 2022, putting the company’s pre-money valuation at $40 million. Vivo Capital, Digitalis Ventures and RiverVest Venture Partners also participated in the round. The company is a developer of protein-based drugs for regulated, context-dependent activity.
Oceanbio: The company raised GBP 75.7 million of venture funding from K50 Ventures and other undisclosed investors on November 15, 2022, putting the company’s pre-money valuation at GBP 870 million. The company is a developer of novel therapies designed to treat common nervous system disorders.
Rezo Therapeutics: The company raised $78 million of Series A venture funding in a deal led by SR One, a16z Bio + Health and Norwest Venture Partners on November 17, 2022. Liquid 2 Ventures, Hawktail and SV Angel also participated in the round. The company’s platform uses integrated data from proteomics, genetics, structural biology, and chemical biology.
Haystack Oncology: The company raised $67 million of Series A venture funding in a deal led by Catalio Capital Management on November 16, 2022. Bruker, Exact Sciences and Alexandria Venture Investments also participated in the round. The company is a developer of a liquid biopsy diagnostic technology designed to optimize treatment strategies and dramatically improve outcomes for patients with cancer.
A2 Biotherapeutics: The company raised $60.9 million of venture funding from undisclosed investors on November 16, 2022. The company is a developer of a cell therapy designed to cure cancer via tumor-specific targeting.
Aescape: The company raised $30 million of Series A venture funding in a deal led by Valor Equity Partners and Valor Siren Ventures on November 16, 2022. Alumni Ventures, Crosslink Capital, Alley Robotics Ventures, Fifth Wall, and Kevin Love also participated in the round. The company is a developer of a robotics-enabled massage technology.
Curevo Vaccine: The company raised $26 million of Series A1 venture funding from GC Biopharma, RA Capital Management and Adjuvant Capital on November 16, 2022. Janus Henderson Investors also participated in the round. The company is an operator of a biotechnology firm dedicated to reducing the effects of infectious illnesses and addressing unmet medical needs globally.
Novigenix: The company raised $20 million of Series B venture funding from undisclosed investors on November 15, 2022, putting the company’s pre-money valuation at an estimated $147.6 million. The company is a developer of a precision medicine platform designed for the detection of disease, therapy optimization, and disease recurrence monitoring to improve disease management and patient outcomes.
Nymbl Science: The company raised an estimated $15 million of Series B venture funding in a deal led by Outcomes Collective and Cobalt Ventures on November 14, 2022, putting the company’s pre-money valuation at $20 million. Spock Ventures Management and 450 Ventures also participated in the round. The company is a developer of a physical and cognitive training application designed to facilitate fall reduction.
NKGen Biotech: The company raised $3 million of venture funding from undisclosed investors on an undisclosed date. The company is a developer of cell therapies designed to improve patient outcomes in cancer, autoimmune disease, and neurodegeneration.
Subtle Medical: The company raised an undisclosed amount of Series B venture funding in a deal led by Primavera Capital Group and Eastern Bell Venture Capital on November 17, 2022. Fusion Fund, 3E Bioventures Capital, Delta Capital, Crista Galli Ventures, CatchLight Capital Partners and Banyan Pacific Capital also participated in the round. The company is a developer of a software platform designed to improve medical imaging quality.
